Overview
L’Oréal announced on October 29, the signature of a license agreement with Dutch biotech Micreos, the world leader in targeted bacterial biotechnology, to join their expertise in biotechnology and the skin microbiome. Under the terms of the agreement, Micreos will give L’Oréal access to its endolysin, a type of active protein in the cosmetic field. With this technology, it is possible for the first time to target only undesirable bacteria in the skin flora, responsible for many skin problems, while sparing ‘good’ types.
McDermott Will & Emery acted as counsel along with L’Oréal with Anne-France Moreau, Marion Abecassis and Raphaëlle Monjou on licensing matters as well as with Antoine Vergnat and Côme de Saint Vincent on tax law aspects.
Micreos was advised by Jones Day.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
